Workflow
Bio-Rad Laboratories, Inc. (BIO) Launches New Instruments, Boosts Molecular Testing Reach
Bio-RadBio-Rad(US:BIO) Yahoo Financeยท2025-09-18 14:39

Core Insights - Bio-Rad Laboratories, Inc. is identified as one of the most oversold healthcare stocks in 2025, yet it continues to enhance its product portfolio and market presence [1][5] Group 1: Growth Drivers - The droplet digital PCR (ddPCR) platform, particularly the QX600 system, is a key growth driver for the company, with expectations of mid-single-digit revenue growth in 2025 [2] - The acquisition of Stilla Technologies aims to enhance ddPCR capabilities and facilitate entry into new molecular testing markets [2] Group 2: Product Launches - Bio-Rad has launched several new products to strengthen its diagnostics and research offerings, including the EZ-Check Salmonella spp. Kit, StarBright dyes for spectral flow cytometry, and the XP-Design Assay Salmonella Serotyping solution [3] - In bioprocess chromatography, the company expanded its offerings with Nuvia wPrime 2A media and Foresight Pro prepacked columns, supporting scalable biomolecule purification and GMP-ready biotherapeutic production [4] Group 3: Market Performance - Despite challenges in the U.S. academic and government sectors, Bio-Rad is experiencing improved performance in international markets, particularly in Japan and Korea [5] - The company reported strong Q2 results driven by chromatography and consumables, with plans for a capital markets day in spring 2026 to outline further growth strategies [5]